All Work

Jon C. Ogg

Why Analysts See Pacira Pharma in a Night and Day Contrast

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) has found itself in the middle of a great opportunity but not being able to make the last mile of the race. Unfortunately, pain management in a non-opioid treatment…

Jon C. Ogg · 8 years ago

Cemex Upgrade Sees Bad News All Priced In

CEMEX SAB de C.V. (NYSE: CX) has had a rough year, with much of the ongoing trade war risks putting Mexico at risk due to NAFTA being renegotiated by the White House. There are…

Jon C. Ogg · 8 years ago

More Outflows From Equity Funds Than the Market Can Handle

There is an age-old saying in investing in the stock market that earnings drive stock prices. That may be true on the fundamental side of investing theory, but certain mechanics in the market actually…

Jon C. Ogg · 8 years ago